The drug-loaded immunoliposomes were able to reverse EGFRT790M-positive NSCLC resistance to gefitinib through the regulation of ROS/NOX3/MsrA axis and reconfiguration of TAMs [162,197]. Here, MSRA is linked to non-small cell lung carcinoma.